Biohaven Ltd.
A clinical-stage biopharmaceutical company based in New Haven, Connecticut, Biohaven develops therapies for serious neurological and brain conditions that lack good treatments. Founded in 2013 by psychiatrist Dr. Vlad Coric, it created the migraine medicine Nurtec ODT, which was sold to Pfizer in 2022; the remaining research pipeline was spun off into today's independent Biohaven. Its name blends "bio" with "haven," a nod to its New Haven home, and it now works on candidates like the investigational drug troriluzole for the inherited disorder spinocerebellar ataxia.
Bought 3.33M
Granted 14.3K · Bought 666.7K
Bought 400.0K
Granted 4.3K
Granted 3.8K
Granted 2.5K · Bought 17.0K
Granted 4.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Childs John WDirector · 1 transaction | +54.3% | 9.87M | — | 3.33M | — |
| Coric VladChief Executive Officer, Director · 4 transactions | +21.2% | 3.86M | 14.3K | 666.7K | — |
| Bailey GregoryDirector · 1 transaction | +24.7% | 2.02M | — | 400.0K | — |
| Buten MatthewChief Financial Officer · 2 transactions | +1.1% | 198.2K | 4.3K | — | — |
| Gentile KimberlySVP, Clinical Operations · 2 transactions | +1.8% | 101.5K | 3.8K | — | — |
| Clark George C.VP, Chief Accounting Officer · 3 transactions | +25.7% | 87.0K | 2.5K | 17.0K | — |
| Car BruceChief Scientific Officer · 2 transactions | +8% | 40.1K | 4.8K | — | — |
| Mehta KishanDirector · 2 transactions | — | 22.7K | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +4.42M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.